Skip to Content

Clinical Trial Details

Standard Hormone and Radiation Versus Standard Hormone Higher Dose Radiation Plus TAK 700

Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRh Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRh Agonist and TAK-700 (Orteronel) for Men with High Risk Prostate Cancer.

Objective

To determine if patients with high risk disease have a longer survival time with standard treatment (hormone treatment and radiotherapy) versus standard treatment with the addition of 24 months of TAK-700.

Inclusion Criteria:
Must be enrolled within 180 days of diagnosis.

Exclusion Criteria:
No testosterone use for 90 days before enrollment. No prior radiation or chemotherapy. No previous hormone treatment. No previous cardiac history.

IRB Protocol Number
RTOG 1115

Clinical Trial Categories

  • Prostate Cancer
Contact
Margaret White, RN OCN, CC at 603-232-8908

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000